BioRestorative Therapies, Inc. Signs New Executive Employment Agreement with Francisco Silva
Key Points of the Report
-
Francisco Silva Appointed as Vice President of Research and Development, Secretary:
BioRestorative Therapies, Inc. (“the Company”) has entered into a new executive employment agreement with Francisco Silva, effective June 10, 2026. Mr. Silva will serve as Vice President of Research and Development and Secretary, reporting directly to the CEO. -
Compensation and Benefits:
- Annual base salary set at \$575,000, subject to taxes and withholdings.
- Eligibility for an annual discretionary bonus of up to 50% of base salary, based on performance and Board approval.
- Option grants under the Company’s 2021 Stock Incentive Plan (or any successor plan), with specific grants to be determined annually based on the recommendation of an independent third-party compensation consultant.
- Four weeks of paid vacation per year, with accrual and carryover limitations (maximum six weeks of earned but unused vacation).
- Standard employee benefits and expense reimbursement as per company policy.
-
Term and Termination Provisions:
- Initial term of three years, with automatic one-year renewals unless either party provides 90 days’ written notice of non-renewal.
- Severance protections: If terminated “Without Cause” or upon resignation for “Good Reason”, Mr. Silva is entitled to a cash severance of 1.5x (salary + maximum bonus), accelerated vesting of all outstanding equity awards, and 1.5 years of COBRA health coverage at company expense, subject to execution of a general release.
- “Good Reason” includes material diminution in duties, material reduction in salary/benefits, forced relocation over 50 miles, or a Change in Control event.
- If terminated “With Cause” or resignation without Good Reason, only accrued obligations are payable.
-
Change in Control Provisions:
- Upon a qualifying Change in Control (e.g., acquisition of >50% of voting shares, change in Board majority, or merger/disposition of substantially all assets), Mr. Silva will receive the full Cash Severance Amount and immediate vesting of all equity awards, regardless of whether his employment is terminated.
- This is a “double-trigger” provision, which can be highly relevant in M&A scenarios and may impact share valuation and potential takeover premiums.
-
Restrictive Covenants and IP Protection:
- One-year non-compete and non-solicitation clause post-termination, covering competitive activities in the US, solicitation of employees, customers, or business partners, and hiring of Company personnel.
- All inventions, modifications, and IP developed during employment are “work made for hire” and the property of the Company.
-
Legal and Regulatory Compliance:
- Agreement is governed by New York law, with mandatory submission to New York courts.
- Contains standard confidentiality, cooperation, and release-of-claims provisions, including a general release upon receipt of severance.
- Includes compliance with Sections 409A, 280G, and 4999 of the Internal Revenue Code, addressing tax treatment and golden parachute rules.
Shareholder-Relevant and Price-Sensitive Information
- Executive Retention and Incentives: The signing of a robust long-term employment agreement with a senior R&D leader signals management stability and continuity for BioRestorative’s scientific programs. The terms are generous and competitive, which may improve executive retention and support ongoing R&D initiatives, a key driver for a biotech company.
- Change in Control Provisions: The “single-trigger” acceleration of equity and significant cash severance upon a Change in Control event could impact negotiations and economics in any future M&A or partnership discussions. Investors should be aware that these provisions may increase the cost of a transaction or influence the structure of any potential acquisition, potentially creating additional value for management.
- Accelerated Equity Vesting: Immediate vesting of equity awards in the event of a qualifying termination or Change in Control could result in dilution to shareholders and should be considered when evaluating the Company’s share structure and potential future events.
- Non-Compete and IP Provisions: Strong restrictions on post-employment competition and stringent assignment of IP protect the Company’s proprietary technologies, which may reassure investors about the protection of future value derived from R&D.
- Disclosure of Material Agreements: The public filing of this agreement and its terms (including salary, bonus, severance, and equity arrangements) provides transparency for shareholders and potential acquirers, and is considered material from a governance and compensation perspective.
Additional Details for Investors
- Reporting Structure: Francisco Silva will report directly to the CEO and will be accountable for leading all scientific and clinical programs, research strategy, IP development, publication of research, regulatory compliance, and management of research operations.
- Vacation and Benefits: Four weeks of vacation per year, with maximum accrual of six weeks, and eligibility for all standard company benefits.
- Conditions for Severance: Severance and COBRA benefits are contingent upon signing a general release of claims. Any breach of post-employment obligations (e.g., non-compete) results in forfeiture and clawback of severance.
- Legal Protections: The agreement includes extensive representations and warranties, dispute resolution provisions, and is binding on successors and assigns.
Potential Impact on Share Price
The appointment and retention of a key executive under competitive terms, with substantial equity and severance protections, is a material development for BioRestorative Therapies, Inc. The agreement provides strong incentives for Mr. Silva to drive the Company’s research and development initiatives, while also introducing financial commitments in the event of a Change in Control or certain terminations. These terms are likely to be viewed as supportive of management stability, but may also be scrutinized by investors in the context of M&A activity, potential dilution, and executive compensation practices.
The Change in Control provisions, in particular, are potentially price-sensitive, as they may influence the outcome and structure of any future strategic transactions involving the Company.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full employment agreement and consult with their own advisors before making any investment decisions. Actual outcomes may differ from those discussed, and future events may impact the terms and consequences described above.
